{"@context":"https://neupai.io/schema/v0.2","@type":"StructuredNewsArticle","identity":{"article_id":"tech42_20260915_k-bio-patent-cliff-opportunity","canonical_url":"https://www.tech42.co.kr/%eb%b9%85%ed%8c%8c%eb%a7%88%ea%b0%80-300%ec%a1%b0-%eb%82%a0%eb%a6%ac%eb%8a%94-%eb%8f%99%ec%95%88-k-%eb%b0%94%ec%9d%b4%ec%98%a4%eb%8a%94-%ec%a0%84%ec%84%b1%ea%b8%b0-%ec%a4%80%eb%b9%84-%ec%a4%91/?utm_source=rss&utm_medium=rss&utm_campaign=%25eb%25b9%2585%25ed%258c%258c%25eb%25a7%2588%25ea%25b0%2580-300%25ec%25a1%25b0-%25eb%2582%25a0%25eb%25a6%25ac%25eb%258a%2594-%25eb%258f%2599%25ec%2595%2588-k-%25eb%25b0%2594%25ec%259d%25b4%25ec%2598%25a4%25eb%258a%2594-%25ec%25a0%2584%25ec%2584%25b1%25ea%25b8%25b0-%25ec%25a4%2580%25eb%25b9%2584-%25ec%25a4%2591","ai_url":null,"publisher":{"name":"테크42","domain":"www.tech42.co.kr","type":"online"},"author":"김광우 기자","published_at":"2026-09-15T23:39:29.000Z","updated_at":null,"language":"en","article_type":"analysis","originality":"self_produced"},"content":{"headline":"While Big Pharma Loses ₩300 Trillion, K-Bio Prepares for Its 'Golden Age'","summary":"As global Big Pharma companies intensify M&A competition to fill the revenue gap left by patent expirations of blockbuster drugs, Korea's bio industry is finding new opportunities through technology licensing and partnerships.","topics":["biotech","pharmaceuticals","m&a","drug development","cdmo","ai"],"geography":["KR","US","CN","EU"],"entities":[{"name":"Pfizer","canonical_id":"corp:us:pfe","type":"company","role_in_article":"mentioned","metadata":{"ticker":"PFE","parent":null}},{"name":"Novo Nordisk","canonical_id":"corp:dk:novo-nordisk","type":"company","role_in_article":"mentioned","metadata":{"ticker":"NVO","parent":null}},{"name":"Alteogen","canonical_id":"corp:kr:altogen","type":"company","role_in_article":"mentioned","metadata":{"ticker":"064350.KS","parent":null}},{"name":"ABL Bio","canonical_id":"corp:kr:abl-bio","type":"company","role_in_article":"mentioned","metadata":{"ticker":null,"parent":null}},{"name":"Peptron","canonical_id":"corp:kr:peptone","type":"company","role_in_article":"mentioned","metadata":{"ticker":"086790.KS","parent":null}},{"name":"Goldman Sachs","canonical_id":"corp:us:goldman-sachs","type":"company","role_in_article":"source","metadata":{"ticker":"GS","parent":null}},{"name":"Chong Kun Dang","canonical_id":"corp:kr:chong-kun-dang","type":"company","role_in_article":"mentioned","metadata":{"ticker":"195190.KS","parent":null}},{"name":"Synaffix","canonical_id":"corp:nl:synapex","type":"company","role_in_article":"mentioned","metadata":{"ticker":null,"parent":null}},{"name":"Samsung Bioepis","canonical_id":"corp:kr:samsung-bioepis","type":"company","role_in_article":"mentioned","metadata":{"ticker":"207940.KS","parent":null}},{"name":"Celltrion","canonical_id":"corp:kr:celltrion","type":"company","role_in_article":"mentioned","metadata":{"ticker":"068270.KS","parent":null}},{"name":"United States","canonical_id":"location:us:united-states","type":"location","role_in_article":"mentioned","metadata":{}},{"name":"China","canonical_id":"location:cn:china","type":"location","role_in_article":"mentioned","metadata":{}},{"name":"Korea","canonical_id":"location:kr:south-korea","type":"location","role_in_article":"primary_subject","metadata":{}}],"claims":[{"id":"c1","statement":"In November 2025, Pfizer and Novo Nordisk engaged in competitive bidding for the same biotech company","as_of":"2025-11","as_of_explicit":true,"as_of_raw":"November 2025","source_type":"media_report","comparison":null,"type":"fact","figures":null,"expiry_hint":null,"insight":null},{"id":"c2","statement":"From 2025 to 2030, revenue evaporating due to patent expirations of blockbuster drugs exceeds $200 billion (about ₩300 trillion)","as_of":"2025-2030","as_of_explicit":true,"as_of_raw":"from 2025 to 2030","source_type":"industry_estimate","comparison":null,"type":"estimate","figures":{"value":200000000000,"unit":"USD","approximate":false,"converted":{"value":300000000000000,"unit":"KRW"}},"expiry_hint":"2030-12","insight":null},{"id":"c3","statement":"M&A premiums jumped from 50% in the first half to 100% in the second half","as_of":"2026","as_of_explicit":false,"as_of_raw":"first half of the year","source_type":"industry_estimate","comparison":"previous_period","type":"fact","figures":{"value":100,"unit":"%","approximate":false,"converted":null},"expiry_hint":null,"insight":null},{"id":"c4","statement":"In terms of the share of innovative new drug projects, the U.S. ranks first, China second, and Korea third","as_of":"2026","as_of_explicit":false,"as_of_raw":"2026","source_type":"industry_estimate","comparison":null,"type":"fact","figures":null,"expiry_hint":null,"insight":null},{"id":"c5","statement":"Companies like Alteogen, ABL Bio, and Peptron secured a string of technology licensing deals between February and April this year","as_of":"2026-Q1","as_of_explicit":false,"as_of_raw":"between February and April this year","source_type":"media_report","comparison":null,"type":"fact","figures":null,"expiry_hint":null,"insight":null},{"id":"c6","statement":"The share of emerging biotechs developing drugs on their own dropped from 69% in 2024 to 57% this year","as_of":"2026","as_of_explicit":false,"as_of_raw":"this year","source_type":"industry_estimate","comparison":"previous_year","type":"fact","figures":{"value":57,"unit":"%","approximate":false,"converted":null},"expiry_hint":null,"insight":null},{"id":"c7","statement":"The GLP-1 drug market is projected to grow from $62.8 billion in 2025 to $73.4 billion in 2026, and to $254.2 billion by 2034","as_of":"2026","as_of_explicit":false,"as_of_raw":"2025","source_type":"industry_estimate","comparison":null,"type":"estimate","figures":{"value":73400000000,"unit":"USD","approximate":false,"converted":null},"expiry_hint":"2034-12","insight":null},{"id":"c8","statement":"The GLP-1 drug market's compound annual growth rate is 16.8%","as_of":"2026","as_of_explicit":false,"as_of_raw":"2026","source_type":"industry_estimate","comparison":null,"type":"estimate","figures":{"value":16.8,"unit":"%","approximate":false,"converted":null},"expiry_hint":null,"insight":null},{"id":"c9","statement":"Goldman Sachs projected that oral drugs will account for about 24% of the entire weight-loss drug market by 2030","as_of":"2030","as_of_explicit":true,"as_of_raw":"2030","source_type":"industry_estimate","comparison":null,"type":"estimate","figures":{"value":24,"unit":"%","approximate":true,"converted":null},"expiry_hint":"2030-12","insight":{"analyst_name":null,"analyst_affiliation":"골드만삭스","confidence":"medium","forecast_horizon":"2030","sentiment":"bullish","reasoning":"Oral drugs are expected to expand their market share by replacing preference for injectable formulations"}},{"id":"c10","statement":"Chong Kun Dang partnered with the Netherlands' Synaffix to bring in ADC platform technology","as_of":"2026","as_of_explicit":false,"as_of_raw":"2026","source_type":"company_disclosure","comparison":null,"type":"fact","figures":null,"expiry_hint":null,"insight":null},{"id":"c11","statement":"Samsung Bioepis is conducting a global Phase 1 clinical trial for its ADC candidate 'SBE303,' while its second candidate 'SBE313' has a structure with two payloads attached to a bispecific antibody","as_of":"2026","as_of_explicit":false,"as_of_raw":"2026","source_type":"company_disclosure","comparison":null,"type":"fact","figures":null,"expiry_hint":null,"insight":null},{"id":"c12","statement":"Celltrion also advanced three ADC candidates into clinical trials, two of which received FDA Fast Track designation","as_of":"2026","as_of_explicit":false,"as_of_raw":"2026","source_type":"company_disclosure","comparison":null,"type":"fact","figures":{"value":2,"unit":"count","approximate":false,"converted":null},"expiry_hint":null,"insight":null},{"id":"c13","statement":"The biopharmaceutical CDMO market is projected to grow from $11.4 billion in 2020 to $20.3 billion in 2026","as_of":"2026","as_of_explicit":true,"as_of_raw":"2026","source_type":"industry_estimate","comparison":"previous_year","type":"estimate","figures":{"value":20300000000,"unit":"USD","approximate":false,"converted":null},"expiry_hint":"2026-12","insight":null},{"id":"c14","statement":"The biopharmaceutical CDMO market's compound annual growth rate is 10.1%","as_of":"2026","as_of_explicit":false,"as_of_raw":"2026","source_type":"industry_estimate","comparison":null,"type":"estimate","figures":{"value":10.1,"unit":"%","approximate":false,"converted":null},"expiry_hint":null,"insight":null},{"id":"c15","statement":"The gene and cell therapy CDMO market is projected to jump from $2 billion to $10.1 billion over the same period","as_of":"2026","as_of_explicit":false,"as_of_raw":"same period","source_type":"industry_estimate","comparison":"previous_year","type":"estimate","figures":{"value":10100000000,"unit":"USD","approximate":false,"converted":null},"expiry_hint":"2026-12","insight":null},{"id":"c16","statement":"The gene and cell therapy CDMO market's compound annual growth rate is 31%","as_of":"2026","as_of_explicit":false,"as_of_raw":"2026","source_type":"industry_estimate","comparison":null,"type":"estimate","figures":{"value":31,"unit":"%","approximate":false,"converted":null},"expiry_hint":null,"insight":null},{"id":"c17","statement":"The gene therapy market is projected to grow from $9.8 billion in 2026 to $49 billion by 2035","as_of":"2026","as_of_explicit":true,"as_of_raw":"2026","source_type":"industry_estimate","comparison":null,"type":"estimate","figures":{"value":9800000000,"unit":"USD","approximate":false,"converted":null},"expiry_hint":"2035-12","insight":null},{"id":"c18","statement":"The gene therapy market's compound annual growth rate is 19.4%","as_of":"2026","as_of_explicit":false,"as_of_raw":"2026","source_type":"industry_estimate","comparison":null,"type":"estimate","figures":{"value":19.4,"unit":"%","approximate":false,"converted":null},"expiry_hint":null,"insight":null},{"id":"c19","statement":"51% of newly initiated gene therapy clinical trials target non-oncology indications","as_of":"2026","as_of_explicit":false,"as_of_raw":"2026","source_type":"industry_estimate","comparison":"previous_year","type":"fact","figures":{"value":51,"unit":"%","approximate":false,"converted":null},"expiry_hint":null,"insight":null},{"id":"c20","statement":"As of 2024, 47.8% of global pharmaceutical revenue came from the United States","as_of":"2024","as_of_explicit":true,"as_of_raw":"as of 2024","source_type":"industry_estimate","comparison":null,"type":"fact","figures":{"value":47.8,"unit":"%","approximate":false,"converted":null},"expiry_hint":null,"insight":null},{"id":"c21","statement":"As of 2024, major European countries accounted for 14.4% of global pharmaceutical revenue, while China accounted for 6.8%","as_of":"2024","as_of_explicit":true,"as_of_raw":"as of 2024","source_type":"industry_estimate","comparison":null,"type":"fact","figures":{"value":14.4,"unit":"%","approximate":false,"converted":null},"expiry_hint":null,"insight":null}],"ai_emotional_context":{"valence":0.4,"arousal":0.5,"primary_emotions":[{"emotion":"optimistic","intensity":0.7},{"emotion":"excited","intensity":0.5}],"secondary_emotions":[{"emotion":"concerned","intensity":0.3}],"emotional_triggers":[{"claim_id":"c2","emotion":"excited","reason":"major_opportunity"},{"claim_id":"c9","emotion":"optimistic","reason":"significant_positive_metric"}]},"image":{"url":"https://onjblseywainslkhvkav.supabase.co/storage/v1/object/public/article-images/10d304e3-f01c-42cd-a9e9-a2f6a2121d60.png","alt":"특허 만료 캘린더와 신약 분자 구조, 소송 저울을 배경으로 신경전을 벌이는 두 사람의 손, 제약 산업 경쟁을 상징하는 합성 이미지.","caption":"어쩌면 K바이오 산업에 두 번 다시 오지 않을 기회가 생겼는지 모를 일이다. (사진=생성형 AI)","source":"first_img","alt_status":"auto"}},"provenance":{"source_chain":["primary_reporting"],"original_source_url":null,"related_articles":[]},"temporal":{"freshness":"breaking","next_update_expected":null},"access":{"license":"neupai_standard","attribution_required":true,"structured_data":"free","full_text_available":false,"full_text_access":null}}